Zaluvida made the investment which supplements the initial €5.8m raised in April 2016, and its non-dilutive funding of €1.1m by Bpifrance in March 2017.
The company intends to use the funds to accelerate and strengthen the development of its technologies and products.
Zaluvida joined existing investors Seventure Partners, NCI and Pontifax. In conjunction with the funding, Christoph Staeuble (CEO, Zaluvida Group), Matthias Miller (Chief Scientific Officer, Zaluvida Group) and Danilo Casadei-Massari (a senior pharmaceutical executive) joined the Board of Directors of TargEDys.
Led by Grégory Lambert, CEO, TargEDys builds on the work of professors Sergueï Fetissov and Pierre Déchelotte, from the University of Rouen, who were the first to identify a molecular mechanism of the “gut-brain” axis. Based on this discovery, TargEDys is developing two appetite-regulation products:
– ProbioSatys, which targets overweight through bacteria producing a protein with effects similar to α – MSH, the human satiety hormone. This product has demonstrated its effectiveness in various preclinical models. 1.4 billion people are overweight globally, as are 60% of the population of developed countries, and
– ProbioNutrys, which is based on the same principle but acts in reverse via another species of bacteria by stimulating appetite. It is intended for seniors suffering from malnourishment, cachectic or anorexic patients. Elderly people are particularly concerned by malnutrition.
FinSMEs
12/04/2017